Locally Advanced Pancreatic Cancer Clinical Trial
Official title:
Phase I Study of Concurrent Nab-Paclitaxel + Gemcitabine With Hypofractionated, Ablative Proton Therapy for Locally Advanced Pancreatic Cancer
The purpose of this study is to determine the maximum tolerated dose of the chemotherapy drugs nab-paclitaxel and gemcitabine when combined with hypofractionated ablative proton therapy for the treatment of locally advanced pancreatic cancer. You will receive proton therapy once a day (Monday - Friday) for 3 weeks. Participants will also receive chemotherapy on each Monday of those three weeks.
The investigators propose a phase I trial to determine the maximum tolerable dose (MTD) and the recommended dose for phase II (RP2D) of concurrent nab-paclitaxel + gemcitabine in combination with ablative IMPT delivered as a fixed dose of 67.5 Gy in 15 fractions daily fractions with 5 fractions per week. In contrast to prior pancreatic cancer studies of chemoradiotherapy which utilized photon RT to treat gross disease and elective lymph nodes (1,2) the proposed study is hypothesized to reduce toxicity risk by limiting highly conformal IMPT to the gross tumor volume. Furthermore, to increase the margin of safety in a manner similar to published data from MDACC (3), the high dose region will be limited to areas at least 5 mm from nearby GI structures (duodenum, small bowel, stomach, etc.). Regions within this area will be treated only to 37.5 Gy in 15 fractions. This dose limitation is also important given that paclitaxel, in addition to increasing systemic efficacy, is a known radiosensitizer (1). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Completed |
NCT01628458 -
Safety Study of Radiofrequency Ablation of Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04276857 -
Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer
|
N/A | |
| Not yet recruiting |
NCT05988372 -
Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)
|
Phase 2 | |
| Completed |
NCT00744640 -
Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03126435 -
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
|
Phase 3 | |
| Completed |
NCT02035072 -
Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.
|
Phase 2 | |
| Enrolling by invitation |
NCT01063192 -
A Study of Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT06429904 -
Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT03885219 -
Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03468335 -
2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
|
Phase 3 | |
| Not yet recruiting |
NCT03443921 -
Divestment for Artery-involved Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT03257033 -
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
|
Phase 3 | |
| Completed |
NCT02578732 -
FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
|
Phase 2 | |
| Recruiting |
NCT04789980 -
Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY
|
||
| Completed |
NCT00644618 -
Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy
|
Phase 3 | |
| Recruiting |
NCT03682289 -
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
|
Phase 2 | |
| Terminated |
NCT02404363 -
Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy
|
Phase 3 | |
| Active, not recruiting |
NCT06353581 -
Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX
|
Phase 2 | |
| Not yet recruiting |
NCT03815461 -
Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer
|
Phase 2 |